PharmaVentures acts as the exclusive M&A advisor on the successful sale of Phasefocus to Bruker

LONDON, March 19, 2024 /PRNewswire/ -- PharmaVentures is pleased to announce that it acted as the exclusive advisor to Phasefocus Holdings Limited on its sale to Bruker (NASDAQGS:BRKR). Phasefocus is a privately held company that has leading expertise in imaging, image processing algorithms and imaging platform. Phasefocus has deployed their expertise to develop a novel optical microscope, called Livecyte, for label-free cell imaging. Phasefocus' microscopy capabilities will enhance Bruker's existing portfo ...